Caris Life director buys 68K shares at $14.56

Caris Life Sciences director Jon Halbert reported an open-market purchase of 68,000 shares of Common Stock on May 15, 2026, at a weighted average price of $14.56 per share, through LAH Investments, Ltd..

Rhea-AI Filing Summary

Caris Life Sciences director Jon Halbert reported an open-market purchase of 68,000 shares of Common Stock on May 15, 2026, at a weighted average price of $14.56 per share, through LAH Investments, Ltd.. These shares were bought in multiple trades between $14.49 and $14.60 per share. Following this transaction, LAH Investments, Ltd. held 704,598 shares indirectly, a family trust held 637,887 shares indirectly, and Halbert held 118,621 shares directly. Some indirect holdings include shares received in pro rata distributions exempt under Rule 16a-9, and Halbert disclaims beneficial ownership except to the extent of his pecuniary interest.

Filing Explained

This is a completed holder-level purchase: the director reports 704,598 indirectly held shares, without a disclosed issuer-level capital change.

The July 13 Form 4, which reports an insider transaction, discloses that director Jon Russel Denton completed an open-market purchase of 68,000 Caris common shares on May 15, 2026.

The structural effect disclosed is at the reporting person's holdings level: 704,598 shares are reported as beneficially owned indirectly through LAH Investments, Ltd., rather than as a new issuer financing or share issuance.

The reported purchase price was a weighted average of $14.56, with individual purchase prices ranging from $14.49 to $14.60; the filing says the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest. No Rule 10b5-1 trading plan is disclosed in the supplied filing. In the supplied 90-day insider record, the two listed transactions are purchases totaling 99,050 shares, with no sales recorded.

Insider Trade Summary

Net Buyer: 68,000 shares

Net Buy 3 txns

Insider HALBERT JON

Role Director

Bought 68,000 shs ($990K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F2, F3, F4	68,000	$14.56	$990K
holding	Common Stock	--	--	--
holding	Common Stock F1	--	--	--

Holdings After Transaction: Common Stock — 704,598 shares (Indirect, By LAH Investments, Ltd.); Common Stock — 118,621 shares (Direct); Common Stock — 637,887 shares (Indirect, By Family Trust)

Footnotes (4)

1. F1. Includes an aggregate of 23,196 shares received in pro rata distributions exempt pursuant to Rule 16a-9.
2. F2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.49 to $14.60 inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
3. F3. Includes an aggregate of 11,598 shares received in pro rata distributions exempt pursuant to Rule 16a-9.
4. F4. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 07:06 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HALBERT JON

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TEXAS 75039

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								118,621	D
Common Stock								637,887(1)	I	By Family Trust
Common Stock	05/15/2026		P		68,000	A	$14.56(2)	704,598(3)	I	By LAH Investments, Ltd.(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes an aggregate of 23,196 shares received in pro rata distributions exempt pursuant to Rule 16a-9.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.49 to $14.60 inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

3. Includes an aggregate of 11,598 shares received in pro rata distributions exempt pursuant to Rule 16a-9.

4. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Remarks:

	/s/ J. Russel Denton, Attorney-in-Fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)